Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of AG019 Alone or with Teplizumab in Recent-Onset Type 1 Diabetes
NCT03751007Phase 2Completed
- Sponsor
- Precigen
- Start
- Oct 2018
- Primary completion
- Oct 2021
- Modality
- Gene Editing, Gene Silencing, Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of AG019 in type 1 diabetes mellitus (T1D), sponsored by Precigen. Started Oct 2018; status: completed.
02
Drugs
AG019
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03751007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03751007.